Sulfatide-activated type II NKT cells prevent allergic airway inflammation by inhibiting type I NKT cell function in a mouse model of asthma
Sulfatide-activated type II NKT cells prevent allergic airway inflammation by inhibiting type I NKT cell function in a mouse model of asthma
复制标题
硫脂激活的 II 型 NKT 细胞通过抑制哮喘小鼠模型中的 I 型 NKT 细胞功能来预防过敏性气道炎症
DOI：
10.1152/ajplung.00114.2011
复制
发表时间：
2011-12-01
影响因子：
4.9
通讯作者：
Hu, Suping
中科院分区：
文献类型：
--
作者：
Zhang, Guqin;Nie, Hanxiang;Hu, Suping
张刚，聂华，杨军，丁翔，黄勇，于华，李荣，袁忠，胡松。在哮喘小鼠模型中，硫酸脂激活的II型NKT细胞通过抑制I型NKT细胞功能预防过敏性气道炎症美国生理学杂志肺细胞分子生理学301：L975-L984，2011年。首次发表于2011年8月19日; doi：10.1152/ajplung.00114.2011.-哮喘是一种常见的慢性炎症性疾病，涉及许多不同的细胞类型。最近，I型自然杀伤T（NKT）细胞已被证明在哮喘的发展中起着至关重要的作用。然而，II型NKT细胞在哮喘中的作用尚未研究。有趣的是，I型和II型NKT细胞已被证明在抗肿瘤免疫、抗寄生虫免疫和自身免疫中具有相反的作用。我们假设硫苷脂激活的II型NKT细胞可以通过抑制I型NKT细胞功能来预防哮喘中的过敏性气道炎症。引人注目的是，在我们的小鼠模型中，通过硫苷脂给药和硫苷脂活化的II型NKT细胞的过继转移活化II型NKT细胞，导致肺和支气管肺泡灌洗液中炎症细胞浸润减少，BALF中IL-4和IL-5水平降低，血清中卵清蛋白特异性IgE和IgG 1水平降低。此外，发现硫酸脂反应性II型NKT细胞的活化导致I型NKT细胞的功能失活，包括增殖和细胞因子分泌。我们的数据表明，II型NKT细胞激活的糖脂，如硫苷脂，可能作为一种新的方法来治疗过敏性疾病和其他疾病的特点是不适当的I型NKT细胞活化。
Zhang G, Nie H, Yang J, Ding X, Huang Y, Yu H, Li R, Yuan Z, Hu S. Sulfatide-activated type II NKT cells prevent allergic airway inflammation by inhibiting type I NKT cell function in a mouse model of asthma. Am J Physiol Lung Cell Mol Physiol 301: L975-L984, 2011. First published August 19, 2011; doi: 10.1152/ajplung.00114.2011.-Asthma is a common chronic inflammatory disease involving many different cell types. Recently, type I natural killer T (NKT) cells have been demonstrated to play a crucial role in the development of asthma. However, the roles of type II NKT cells in asthma have not been investigated before. Interestingly, type I and type II NKT cells have been shown to have opposing roles in antitumor immunity, antiparasite immunity, and autoimmunity. We hypothesized that sulfatide-activated type II NKT cells could prevent allergic airway inflammation by inhibiting type I NKT cell function in asthma. Strikingly, in our mouse model, activation of type II NKT cells by sulfatide administration and adoptive transfer of sulfatide-activated type II NKT cells result in reduced-inflammation cell infiltration in the lung and bronchoalveolar lavage fluid, decreased levels of IL-4 and IL-5 in the BALF; and decreased serum levels of ovalbumin-specific IgE and IgG1. Furthermore, it is found that the activation of sulfatide-reactive type II NKT cells leads to the functional inactivation of type I NKT cells, including the proliferation and cytokine secretion. Our data reveal that type II NKT cells activated by glycolipids, such as sulfatide, may serve as a novel approach to treat allergic diseases and other disorders characterized by inappropriate type I NKT cell activation.